I like to think about technology and how it can improve our health and our sustainable future.

* * *

I was previously a healthcare investor at Bain Capital Ventures. Prior to that, I worked at Blackstone on financial restructuring and at the World Health Organization on infectious disease policy. I also worked at a biotech company, helping to develop a new drug for tuberculosis (TMC-207). I graduated from Harvard, where I studied Biomedicine. My work has been published in Science, Nature Biotechnology, JAMA, and the New England Journal of Medicine and cited by the Wall Street Journal, Washington Post, and Le Figaro.


Cardiovascular Medicine

The empirical findings of this study raise interesting issues about the future of drug development . . .
— Dr. Califf, Commissioner of the Food and Drug Administration, et al.

Our recent paper in the Journal of the American College of Cardiology (with an accompanying editorial by Dr. Califf and colleagues at FDA) identifies critical changes in cardiovascular drug development and novelty of biological targets over the past decade.


Antibiotic Innovation

Cumulative incidence curves for progression to subsequent phase shown for antibiotics (blue) and non-antibiotic drugs (black). Source: Hwang TJ, et al. Science 2014; 344: 967-969.

Cumulative incidence curves for progression to subsequent phase shown for antibiotics (blue) and non-antibiotic drugs (black). Source: Hwang TJ, et al. Science 2014; 344: 967-969.

Our paper in Science quantifies risks in antibiotic research and development. To assess differential probabilities of success, we merged individual compound data from 1990 to 2012 and fit our data to accelerated failure time models (continued in blog post, Science article)


MultiDrug-Resistant Tuberculosis

Hwang and colleagues recently reviewed the occurrence of adverse events – overall and by type – with particular attention to psychiatric and CNS toxicity. Their published estimates were used for Cycloserine and TZD toxicity . . .
— World Health Organization Expert Committee (2015)

Our research (see Papers for list of publications) on the safety of second- and third-line treatments for drug-resistant tuberculosis was cited in World Health Organization treatment guidelines and contributed to policy changes by national TB programs. In 2015, the study findings led to the inclusion of a new drug on the WHO's Essential Medicines List.


Posts